This announcement is a separate document:
6-K: Gepotidacin Accepted for Priority Review by Us Fda for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.